Anticancer properties of pomolic acid-induced AMP-activated protein kinase activation in MCF7 human breast cancer cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 1, 2012, Pages 105-110

  Youn, Seog Hyeon ^a   Lee, Jin Sun ^a   Lee, Myung Sun ^a   Cha, Eun Young ^a   Thuong, Phuong Thien ^b   Kim, Je Ryong ^a,c   Chang, Eil Sung ^a,c  

^a Chungnam National University College of Medicine   (South Korea)

^b Vietnam National Institute of Medicinal Materials   (Viet Nam)

^c Chungnam National University   (South Korea)

Author keywords

AMP activated protein kinase; Breast cancer; Pomolic acid

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A; ACETYL COENZYME A CARBOXYLASE; CASPASE 3; CASPASE 9; FATTY ACID; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PENTACYCLIC TRITERPENE; POMOLIC ACID; PROTEIN P21; PROTEIN P53; S6 KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL;

ACETYL-COA CARBOXYLASE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CASPASE 9; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FEMALE; G1 PHASE; GENE EXPRESSION; GENES, P53; HUMANS; OLEANOLIC ACID; PHYTOTHERAPY; PLANT EXTRACTS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BIOSYNTHESIS; RIBONUCLEOTIDES; RNA, MESSENGER;

EID: 84862918727     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.105     Document Type: Article

References (24)

1. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat. Prod. Rep., 17, 215-234 (2000).
2. Fernandes J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA, Gattass CR. Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett., 190, 165-169 (2003).
3. Arbuck SG, Dorr A, Friedman MA. Paclitaxel (Taxol) in breast cancer. Hematol. Oncol. Clin. North Am., 8, 121-140 (1994).
4. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, Shieh JC, Chen WJ, Tsai SC, Way TD. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J. Agric. Food Chem., 58, 1584-1592 (2010).
5. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci., 24, 22-25 (1999).
6. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol., 6, 457-470 (2010).
7. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-1625 (2009).
8. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res., 66, 10269-10273 (2006).
9. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res., 1, 369-375 (2008).
10. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun., 321, 161-167 (2004).
11. Ma WW, Jimeno A. Temsirolimus. Drugs Today, 43, 659-669 (2007).
12. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22 (2007).
13. Lee MS, Thuong PT. Stimulation of glucose uptake by triterpenoids from Weigela subsessilis. Phytother. Res., 24, 49-53 (2010).
14. Fernandes J, Weinlich R, Castilho RO, Kaplan MA, Amarante- Mendes GP, Gattass CR. Pomolic acid triggers mitochondria-dependent apoptotic cell death in leukemia cell line. Cancer Lett., 219, 49-55 (2005).
15. Vasconcelos FC, Gattass CR, Rumjanek VM, Maia RC. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest. New Drugs, 25, 525-533 (2007).
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 100, 57-70 (2000).
17. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit. Rev. Oncol. Hematol., 67, 1-7 (2008).
18. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-1305 (2005).
19. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev. Mol. Diagn., 10, 509-519 (2010).
20. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab., 1, 15-25 (2005).
21. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. U.S.A., 97, 3450-3454 (2000).
22. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 108, 1167-1174 (2001).
23. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol. Nutr. Food Res., 53, 1156-1165 (2009).
24. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, De Schrijver E, Van de Sande T, Noël A, Foufelle F, Verhoeven G. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res., 65, 2441-2448 (2005).